anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A fibrous polymer implant loaded with one or more bioactive agents is prepared using a wet spinning technique. Preferably, an aqueous solution of bioactive agent is added to a solution of amphiphilic block copolymer containing hydrophilic blocks such as polyalkylene glycol and hydrophobic blocks such as an aromatic ester dissolved in a first solvent immiscible with water to form an emulsion. The emulsion is injected through a nozzle into a second solvent miscible with the first solvent in which the copolymer is essentially insoluble to form a solid copolymer fiber loaded with the bioactive agent. The fiber is shaped into an implant. Water content of the aqueous solution of bioactive agent affects rate of release of the bioactive agent in vivo. Bioactive agents include peptides, oligopeptides, polypeptides and proteins. The implant may be used as a carrier for controlled drug release or as a scaffold for tissue engineering.
Engage in supervised aerobic exercise for 60 minutes on 3 days per week for 8 weeks. Exercise is performed on a recumbent bike or treadmill at 50-80% of their heart rate reserve.
The intervention includes 4 every other week, 2-hour educational sessions to teach compensatory strategies along with skill development and training. Educational sessions will include content on common cognitive problems experienced by people with T2DM and discussion of compensatory strategies to improve cognitive skills as well as content on behaviors and lifestyle strategies to maintain cognitive functioning. Each participant will use the online training program (BrainHQ/Posit Science) for a minimum of 45 minutes 3 times a week and to record practice times and dates. Tasks in the computer training are arranged so that as the user moves forward, the tasks become more challenging. Each task is in a game-like format.
FIELD: medicine. SUBSTANCE: method involves enterally dropwise administering hydrolyzed enpit during the first 3-4 days after surgical intervention. 15 ml of NK biococktail is additionally enterally administered in bolus dose every day during 6 h long time interval. Active peristalsis manifestations being detected, the patient is transferred to peroral enpit administration 6 times a day at a dose of 25 kcal/kg/day with 30 ml NK biococktail given in one hour after taking meals. EFFECT: enhanced effectiveness of treatment. 1 dwg, 4 tbl
Meconium passage in newborn infants is a developmentally programmed event normally occurring within first 24-48 hours of birth. Intra uterine meconium passage in near term or term fetuses has been associated with feto-maternal stress factors and/or infections, whereas meconium passage in post term pregnancies has been attributed to gastro-intestinal maturity. The meconium staining of amniotic fluid occurs in 12% of all live births per annuum. Aspiration of meconium that occurs during intra uterine life or after delivery with the first few breaths may result in or contribute to respiratory pathology known as meconium aspiration syndrome (MAS) which represents a leading cause of the perinatal morbidity, occurring in 5-20% of all babies born through MSAF.

The routine use of antibiotics in MSAF babies has been advocated for a long time as a part of the conventional treatment. Meconium passage in utero is hypothesized to represent a response to fetal bacterial infection in addition to intrauterine hypoxia. Additionally the rationale for use of antibiotics includes the radiographic similarity of MAS to bacterial pneumonia, in vitro enhancement of bacterial growth in presence of meconium as well as the possibility of meconium induced inhibition of phagocytic activity and respiratory burst response by alveolar macrophages rendering patients with MAS more susceptible to infection. These recommendations however are empirical and the incidence of bacterial infection in neonates born through MSAF as well as in MAS has not been systematically evaluated, to date. With the rising concern about the emergence of resistant strains in neonatal ICUs and the possible side effects of antibiotics (like amino glycosides) including nephrotoxicity and ototoxicity in neonates, a systematically conducted, randomized controlled trial is necessary to assess the utility of antibiotics in the routine management of infants with MSAF and MAS. Hence the purpose of this prospective randomized controlled trial is to compare the clinical course, complications, and infection related outcomes in cases of MSAF and MAS, treated with or without antibiotics therapy
Provided are a cloud technology-based intelligent multi-channel disease diagnostic system and a method. The system comprises a remote symptom diagnostic module, a remote fever testing module, a remote virus testing module, a multi-sensor diagnostic module, a laboratory/hospital diagnostic module, and a cloud interactive diagnostic system used to establish terminal communication, model building, and analysis. The remote virus testing module comprises wearable virus testing and portable virus testing. The cloud interactive diagnostic system analyzes and processes data uploaded by the modules, and provides multiple data services. Further provided is a hierarchical infectious disease treatment and monitoring method implemented by means of the disease diagnostic system. The technical solutions provided by the present invention utilize the combination of a cloud technology platform, a wearable virus testing apparatus, and a multi-channel diagnostic technique, and solve the problem of the prior art in which manually testing for viruses close to the patient carries a risk of infection, and real-time tracing and open-source sharing for infectious disease data cannot be performed.
<P>PROBLEM TO BE SOLVED: To provide a diabetes treatment/prophylactic agent etc. which is effective for treating and preventing diabetes, does not induce hypoglycemia, is safely used as a therapeutic agent and for therapy, exerts an efficacy higher than those of conventional agents and uses active ingredients discovered from a natural vegetable food.  <P>SOLUTION: The diabetes treatment/prophylactic agent comprises a soyasaponin-containing composition containing soyasaponins as active ingredients for lowering the blood glucose level. Hyperglycemic condition is prevented or improved by lowering the blood glucose level by orally taking soyasaponins or the soyasaponins-containing composition. A health food for preventing hyperglycemic condition is prepared by compounding soyasaponins or the soyasaponins-containing composition.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The invention provides a preparation method of angelica volatile oil capsules, which comprises the following steps: preparing gelatin solution and acacia solution respectively; complex coacervation into vesicles: mixing the volatile oil of radix Angelicae sinensis with gelatin solution, dispersing into emulsion, adding acacia solution, stirring well, and regulating pH value; adding formaldehyde aqueous solution for curing. The method of the invention improves the stability of the medicine and leads the capsule core to slow down the oxidative deterioration caused by the influence of light, dampness and heat. The strong smell of the medicine is covered, the smell becomes light after the microcapsule is prepared, and the medication compliance of patients can be improved. The liquid medicine is solidified, and is convenient for storage, transportation and development. Avoiding the irritation of the stomach of the medicine. Can realize slow and controlled release of the medicine, and increase the effective time of the effective components. The microcapsule is used as a preparation intermediate, can be further developed into different dosage forms such as tablets, capsules, injection, patches, ophthalmic preparations and the like, and provides reference for the development of new Chinese angelica oil medicines.
Teriparatide is a drug that is designed to have a similar effect on the body as parathyroid hormone. Parathyroid hormone is made naturally in the body and is released in response to low calcium levels. It helps to maintain bone health and repair bone damage. Parathyroid hormone and medicines like teriparatide can strengthen bones and are often given to people with osteoporosis (a condition that weakens bones, making them more likely to break) to reduce the risk of fractures. Recent studies have also shown benefits in people with stress fracture injuries, a form of bone damage sometimes caused by repetitive exercise. The investigators want to know if teriparatide is also beneficial to healthy, younger people who have a stress fracture injury.
In order to minimize the complication rates and voice disturbances during thyroidectomy, intraoperative nerve monitoring(IONM) is a widely used intervention. In this study investigators will compare conventional surgery with IONM used surgery. Randomly chosen half of the patients will be operated with IONM. Vagus, recurrent and superior laryngeal nerves will be monitored during surgery and measured for nerve integrity . Rest of the patients will be operated with standard conventional method. All participants will be analyzed with a computer program for their voice quality preoperatively and postoperatively at 14th day of surgery.
Conventional cytogenetics has been the gold standard for chromosomal analysis in prenatal diagnosis. It allows a microscopic examination for any structural abnormalities of chromosome with a turn-around time of 2 to 3 weeks and it is also labour intensive. Array comparative genome hybridisation (aCGH) provides a platform for a higher resolution analysis of chromosomal aberrations in a shorter period of time. The effectiveness of its application in prenatal diagnosis has been examined (Callaway, Shaffer, Chitty, Rosenfeld, \& Crolla, 2013). The main clinical limitation lies on the difficult interpretation of certain copy number variants (CNV). Our previous study has demonstrated an increase diagnostic yield of 3.2% using aCGH over conventional cytogenetics in the first-tier test study and by 6% as a further test in a cohort of fetuses with ultrasound abnormality and normal karyotype findings (Kan et al., 2014). This finding were consistent with the overall reported of 5.2% to 10% increased detection rate by other studies (de Wit et al., 2014; Hillman et al., 2013; Hillman et al., 2011). Various authorities have also approved the use of aCGH as an adjunct diagnostic tool in prenatal cases with fetal ultrasound abnormalities (American College of Obstetricians \& Gynecologists, 2013; Novelli et al., 2012).
BACKGROUND: Microglia play a crucial role in regulating the progression of traumatic brain injury (TBI). In specific, microglia can self-activate and secrete various substances that exacerbate or alleviate the neuroimmune response to TBI. In addition, microRNAs (miRNAs) are involved in the functional regulation of microglia. However, molecular markers that reflect the dynamics of TBI have not yet been found in peripheral tissues.
METHODS: Paired samples of peripheral blood were collected from patients with TBI before and after treatment. Next-generation sequencing and bioinformatics analysis were used to identify the main pathways and biological functions of TBI-related miRNAs in the samples. Moreover, lipopolysaccharide-treated human microglia were used to construct a cellular immune-activation model. This was combined with analysis of peripheral blood samples to screen for highly expressed miRNAs derived from activated microglia after TBI treatment. Quantitative reverse-transcriptase polymerase chain reaction was used to determine the expression levels of these miRNAs, allowing their relationship with the severity of TBI to be examined. Receiver operating characteristic (ROC) curves were constructed to analyse the clinical utility of these miRNAs for determining the extent of TBI.
RESULTS: Sequencing results showed that 37 miRNAs were differentially expressed in peripheral blood samples from patients with TBI before and after treatment, with 17 miRNAs being upregulated and 20 miRNAs being downregulated after treatment. The expression profiles of these miRNAs were verified in microglial inflammation models and in the abovementioned peripheral blood samples. The results showed that hsa-miR-122-5p and hsa-miR-193b-3p were highly expressed in the peripheral blood of patients with TBI after treatment and that the expression levels of these miRNAs were correlated with the patients' scores on the Glasgow Coma Scale. ROC curve analysis revealed that abnormally high levels of expression of hsa-miR-122-5p and hsa-miR-193b-3p in peripheral blood have some clinical utility for distinguishing different extents of TBI and thus could serve as biomarkers of TBI.
CONCLUSION: Abnormally high levels of expression of hsa-miR-122-5p and hsa-miR-193b-3p in the peripheral blood of patients with TBI were due to the activation of microglia and correlated with the severity of TBI. This discovery may help to increase understanding of the molecular pathology of TBI and guide the development of new strategies for TBI therapy based on microglial function.
The invention provides a preparation method of a medlar extract rich in medlar acid. The invention adopts a yeast biological fermentation method to obviously improve the content of the lycium barbarum acid. The prepared fructus Lycii extract with Lycium acid content of 3.0% widens its application range, and can be used in anti-saccharification product, food for diabetes patients, etc. And can be used as a slow release agent of ascorbic acid, has wide application prospect and use value in the cosmetic market, the pharmaceutical industry and the food preservative, and has great social benefit and economic value. Compared with the existing fine filtration, ultrafiltration and nanofiltration membrane processes, the method has the remarkable advantages of simple and convenient operation, high production efficiency, difficult pollution and the like. Has no special requirements on production equipment, simple operation, strong practicability and higher application value, and is suitable for industrial production.
PURPOSE: To obtain a cosmetic as a transparent two-phase composition having surfactant action, comprising a phase containing a liquid organic acid and a 2nd phase containing an alkaline agent. CONSTITUTION: This cosmetic composition comprises a 1st phase containing 0.01-50 wt.% of a liquid organic acid (e.g. isostearic acid) and 0.01-99 wt.% of a pharmaceutically acceptable carrier such as an ester, silicone oil, acidifying agent, thickening agent or antiseptic and a 2nd phase containing 0.5-30 wt.% of an alkaline agent (e.g. triethanolamine) for forming a surfactant through neutralizing the liquid organic acid. This cosmetic is in such multicompartment dispenser form as to separately hold both the phases respectively into different compartments of a dispenser. When the acid and the neutralizing agent are released from the separate compartments, they are mutually blended, forming a surfactant following neutralization.
The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL lidocaine creamwill be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
Mycobacterium avium complex (MAC) is thought to be the most common disseminated bacterial opportunistic infection in AIDS, with clinical prevalence estimates ranging from 15 to 50 percent of all AIDS patients. Clarithromycin, a new macrolide antimicrobial agent, has demonstrated activity against MAC both in the laboratory and in animals. Clinical experience treating AIDS patients with clarithromycin for disseminated MAC is limited. However, early studies have indicated few adverse effects and some improvement in clinical symptoms scores and Karnofsky performance scores over placebo treated patients.

Treatment is randomly assigned so that twice as many patients receive clarithromycin at the lower dose as at an intermediate dose for 12 weeks. Once data becomes available to support dosing patients with clarithromycin at the highest dose, then treatment will be randomly assigned so that twice as many patients receive clarithromycin at the highest dose as at the intermediate dose. Sixteen patients per group (48 patients in all) will be enrolled. Patients exhibiting clinical improvement or clinical cure while on this trial will be allowed to continue on therapy for an additional 6 months. Patients will have clinical evaluations (including the Karnofsky Performance Scale), laboratory evaluations (hematology and chemistry), and blood cultures for MAC performed monthly.
A method and system for managing customer service processes for individual customers and populations of customers. In a specific embodiment within the health care field, a clinician creates or updates a draft care plan for a patient using generic or locally-adapted template metadata and tailors the draft care plan to the particular patient. The draft care plan includes a list of specific services (health care interventions) to be provided to the patient. The draft care plan can be routed to members of an inter-disciplinary team for input. Once finalized, workflow processes are instantiated for each intervention on the care plan. An itinerary is created for any required patient encounters, optimized using an algorithm that considers pre-existing process instances. A workflow automation server manages the execution of each workflow process instance, invoking resources according to workflow process specification metadata and workflow task type metadata. Care plans and encounter itineraries are automatically translated to a patient-understandable form and made available to patients online and via printed copy. Clinical practice and outcomes data are analyzed to identify opportunities for improvement of the metadata. The method and system also allows for the selection of a population of patients, the analysis of population data to identify opportunities for interventions (needed services), and the initiation of population interventions through batch updates to individual care plans.
The primary outcome of this study will be objective measures of cognitive performance measured with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at baseline, crossover, and the end of study. Subjects will receive 1200 mg Niagen and PBO dispensed in randomized blocks. All subjects will receive both.
PCT No. PCT/JP91/00965 Sec. 371 Date Apr. 14, 1992 Sec. 102(e) Date Apr. 14, 1992 PCT Filed Jul. 19, 1991 PCT Pub. No. WO92/03143 PCT Pub. Date Mar. 5, 1992.A central nervous system activator comprising a body or a dried product of a plant belonging to Rutaceae, or an extraction product selected from the group consisting of a lower alkane insoluble portion thereof, a lower fatty acid ester extract of the lower alkane insoluble portion, a lower fatty acid ester-halogenated lower alkane soluble portion of the lower fatty acid ester extract, a limonin fraction of the lower fatty acid ester-halogenated lower alkane soluble portion, and an obacunone fraction of the lower fatty acid ester-halogenated lower alkane soluble portion and a central nervous system activator comprising a limonoid. Further, a taste enhancing food additive comprising the above plant body or dried product or extraction product, or limonoid.
In recent years, with the development of transplantation technology and immunosuppressive agents, kidney transplantation has made considerable progress. However, for metabolic disorders after kidney transplantation, such as new diabetes after kidney transplantation, there is still insufficient awareness. Since 1964, Starlz et al. first discovered and proposed New-onset diabetes after kidney transplantation（NODAT） in patients after renal transplantation. Scholars from all countries have paid considerable attention to it. The Chinese guidelines indicate that NODAT can increase the risk of graft-related complications, such as rejection, graft loss and infection, and ultimately affect the long-term survival of the recipient. In addition, NODAT has also been shown to increase the risk of cardiovascular events, and cardiovascular disease is associated with more than half of kidney transplant deaths. A retrospective study of 567 renal transplant recipients in China showed that the incidence of NODAT was 24.2%. It can be seen that the incidence of new-onset diabetes after renal transplantation is high and has long-term adverse effects on transplant patients. Therefore, there is an urgent need to evaluate and investigate NODAT's therapeutic drug regimens.

According to the study, empagliflozin has a protective effect on the kidney and cardiovascular system, but it has not yet been written into the treatment guidelines for new-onset diabetes after kidney transplantation. Metformin and linagliptin are frequently used in diabetics after renal transplantation, and linagliptin also have a protective effect on the kidneys. Therefore, this experiment wanted to compare the effects between empagliflozin and linagliptin on kidney protection.
The COVID-19 pandemic has been associated with increases in pediatric obesity and widening pre-existing disparities. To better understand the pandemic's long-term impacts, we evaluated trends in obesity across different demographic groups during the pandemic through December 2022. Using a retrospective cohort design, we analyzed electronic health record data from a large pediatric primary care network. Logistic regression models fit using generalized estimating equations estimated odds ratios (ORs) for changes in the level and trajectory of obesity across 2-year month-matched periods: prepandemic (June 2017 to December 2019) and pandemic (June 2020 to December 2022). Among a cohort of 153,667 patients with visits in each period, there was a significant increase in the level of obesity at the pandemic onset [OR: 1.229, 95% confidence interval (CI): 1.211-1.247] followed by a significant decrease in the trend for obesity (OR: 0.993, 95% CI: 0.992-0.993). By December 2022, obesity had returned to prepandemic levels. However, persistent sociodemographic disparities remain.
The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include FGF23 or an active fragment thereof. In one embodiment, the fusion polypeptide comprises (a) a polypeptide comprising fibroblast growth factor 23 (FGF23), or a functionally active variant or derivative thereof, wherein FGF23 has a mutation at one or more of the positions Q 156, C206 and C244; and (b) either a modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or increased serum half-life, or a polypeptide comprising at least one extracellular subdomain of a Klotho protein, or a functionally active variant or derivative thereof; and, optionally (c) a linker. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23), or a functionally active variant or derivative thereof; and a modified Fc fragment, or a functionally active variant or derivative thereof. In various embodiments of the fusion polypeptides, FGF23 has mutations which decrease aggregation and protease-mediated cleavage.